In the SURPASS-2 trial for type 2 diabetes, gastrointestinal adverse events showed a dose-dependent relationship, with higher doses (10 mg and 15 mg) associated with increased frequency of digestive symptoms compared to lower doses (5 mg)
Retatrutide won't reach pharmacies until 2028 at the earliest
GLP-1 activation reduces appetite and slows digestion
The right choice hinges on your starting weight, your other conditions, your insurance, what side effects you can tolerate, and what you actually want out of treatment
Hair Loss: Shedding of hair due to the effect of semaglutide is seen in many cases
Weekly dosing, predictable absorption, and a well-documented safety history are the main reasons most patients and physicians default to it